[1] Wang K, Wang C, Jiang H, et al. Combination of ablation and immunotherapy for hepatocellular carcinoma: where we are and where to go[J]. Front Immunol, 2021, 12: 792781.
[2] Grinspan LT, Villanueva A. Biomarker development using liquid biopsy in hepatocellular carcinoma[J]. Semin Liver Dis, 2022, 42(2): 188-201.
[3] Kieran FH, Cathie MP, Iswar KH. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apopto-sis[J]. Cell, 2003, 114(4):457-467.
[4] Yu FX, Guan KL. The Hippo pathway: regulators and regulatio-ns[J]. Genes Dev, 2013, 27(4): 355-371.
[5] Wang ZL, Lu WH, Zhang YL, et al. The Hippo pathway and viral infections[J]. Front Microbiol, 2020,10:3033.
[6] Pibiri M, Simbula G. Role of the Hippo pathway in liver regeneration and repair: recent advances[J]. Inflamm Regen, 2022, 42(1): 59.
[7] Li H, Wolfe A, Septer S, et al. Deregulation of Hippo kinase signalling in human hepatic malignancies[J]. Liver Int, 2012, 32(1): 38-47.
[8] Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer[J]. Embo Reports, 2014, 15(6): 642-656.
[9] Wu Z, Guan KL. Hippo signaling in embryogenesis and development[J]. Trends Biochem Sci, 2021, 46(1): 51-63.
[10] Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease[J]. Development, 2014, 141(8): 1614-1626.
[11] Meng Z, Moroishi T, Guan KL. Mechanisms of Hippo pathway regulation[J]. Genes Dev, 2016, 30(1): 1-17.
[12] Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas[J]. Cell, 2018, 173(2): 321-337.e10.
[13] Song XH, Xu HW, Wang P, et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation[J]. J Hepatol, 2021, 75(4):888-899.
[14] Piccolo S,Dupont S,Cordenonsi M.The biology of YAP/TAZ: Hippo signaling and beyond[J].Physiol Rev,2014,94(4):1287-1312.
[15] Calses PC, Crawford JJ, Lill JR, et al. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities[J]. Trends Can-cer, 2019, 5(5): 297-307.
[16] Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer[J].Cell,2015,163(4):811-828.
[17] Tanas M, Ma S, Jadaan F, et al. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein[J]. Oncogene, 2016, 35(7): 929-938.
[18] Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward[J]. Nat Rev Cancer, 2021, 21(10): 669-680.
[19] Zhang X, Zhao H, Li Y, et al. The role of YAP/TAZ activity in cancer metabolic reprogramming[J]. Mol Cancer, 2018, 17(1): 134.
[20] Sanjaya A, Goenawan H, Setiawan I, et al. Elaborating the physiological role of YAP as a glucose metabolism regulator:a systematic review[J]. Cell Physiol Biochem, 2021, 55(2): 193-205.
[21] Cox A, Hwang K, Brown K, et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth[J]. Nat Cell Bio, 2016, 18(8): 886-896.
[22] Liu Q, Li J, Zhang W, et al. Glycogen accumulation and phase separation drives liver tumor initiation[J]. Cell, 2021, 184(22): 5559-5576.
[23] Zhu N,Yang R,Wang X, et al. The Hippo signaling pathway: from multiple signals to the hallmarks of cancers[J]. Acta Biochim Biophys Sin,2023, 55(6):904-913.
[24] Yu F, Zhang Y, Park H, et al. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation[J]. Genes Dev, 2013, 27(11): 1223-1232.
[25] Perra A,Kowalik MA,Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer developm-ent[J]. J Hepatol, 2014, 61(5):1088-1096.
[26] Russell JO, Camargo FD. Hippo signalling in the liver: role in development, regeneration and disease[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(5): 297-312.
[27] Xia H, Dai X, Yu H, et al. EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy[J]. Cell death Dis, 2018, 9(3): 269.
[28] Poole C,Van Riggelen J.MYC-Master regulator of the cancer epigenome and transcriptome[J].Genes,2017,8(5):142.
[29] Cancer Genome Atlas Reseanch Netwotk. Comprehensive and integrative genomic characterization of hepatocellular carcino-ma[J]. Cell, 2017, 169(7): 1327-1341.
[30] Xiao WF, Wang JY, Ou C, et al. Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer[J]. Biochem Biophys Res Commun, 2013, 439(2): 167-172.
[31] Wang H, Zhang S, Zhang Y, et al. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis[J]. J Hepatol, 2022, 76(1): 123-134.
[32] Song H, Mak K, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression[J]. Proc Natl Acad Sci, 2010, 107(4): 1431-1436.
[33] Zhou D, Ccnrad C, Xia F, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene[J]. Cancer Cell, 2009, 16(5): 425-438.
[34] Lu L, Li Y, Kim S, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver[J]. Proc Natl Acad Sci, 2010, 107(4): 1437-1442.
[35] Kim W, Khan S, Gvozdenovic-Jeremic J, et al. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis[J]. J Clin Invest, 2017, 127(1): 137-152.
[36] Wang H, Song X, Liao H, et al. Overexpression of mothers against decapentaplegic homolog 7 activates the Yes-Associated Protein/Notch cascade and promotes liver carcinogenesis in mice and humans[J]. Hepatology, 2021, 74(1): 248-263.
[37] Yang Y, Ni M, Zong R, et al. Targeting Notch1-YAP circuit reprograms macrophage polarization and alleviates acute liver injury in mice[J]. Cell Mol Gastroenterol Hepatol, 2023, 15(5): 1085-1104.
[38] Thompson BJ. YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy[J]. Bio Essays, 2020, 42(5):26-33.
[39] Fu M, Hu Y, Lan T, et al. The Hippo signalling pathway and its implications in human health and diseases[J]. Signal Transduct Target Ther, 2022, 7(1):376.
[40] Moya I,Castaldo S,Van Den Mooter L,et al.Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice[J].Science,2019,366(6468):1029-1034.
[41] Wang C, Zhu Z, Liu C, et al. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells[J]. Mol Med Rep, 2015, 11(6): 4101-4108.
[42] Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma[J]. Hepatology, 2009, 49(1): 318-329.
[43] Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer[J]. Nat Rev Cancer, 2013, 13(4): 246-257.
[44] Moloudizargari M, Asghari M, Nabavi SF, et al. Targeting Hippo signaling pathway by phytochemicals in cancer therapy[J]. Semin Cancer Biol, 2022, 80: 183-194.
[45] Yong J, Li Y, Lin S, et al. Inhibitors targeting YAP in gastric cancer: current status and future perspectives[J]. Drug Des Devel Ther, 2021, 15: 2445-2456.
[46] Liu A, Poon R, Luk J. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties[J]. Biochem Biophys Res Commun, 2010, 394(3): 623-627.
[47] Lu L, Finegold M, Johnson R. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration[J]. Exp Mol Med, 2018, 50(1): e423.
[48] Zhou Y, Wang Y, Zhou W, et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway[J]. Cancer Cell Int, 2019, 19: 179.
[49] Han S, Lim J, Cho K, et al. Anti-cancer effects of YAP inhibitor (CA3) in combination with sorafenib against hepatocellular carcinoma (HCC) in patient-derived multicellular tumor spheroid models (MCTS)[J]. Cancers, 2022, 14(11):2733.
[50] Reis H, Bertram S, Pott L, et al. Markers of Hippo-Pathway activity in tumor forming liver lesions[J]. Pathol Oncol Res, 2017, 23(1): 33-39.
[51] Hiromitsu H, Takaaki H, Naomi Y, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression[J]. Cancer Res,2015,75(22):4985-4997.